Dasatinib is a small molecule tyrosine kinase inhibitor that was initially isolated as a dual Src/ABL inhibitor (5), which has been approved by the Food and Drug Administration (FDA) for imatinib-resistant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treatment (6,7). Here, SRC is linked to acute lymphoblastic leukemia.